Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic and Clinical Factors Associated With Metformin Plasma Concentrations Following an Acute Metformin Challenge.

The Journal of clinical endocrinology and metabolism·2026
Same author

Response to the Letter to the Editor Entitled "A Missing Genomic Dimension: The Small but Central Mitochondrial Genome in Diabetic Kidney Disease Genetics".

Kidney international reports·2026
Same author

Porphyromonas gingivalis disrupts hippocampal circadian clock via PI3K/AKT pathway, exacerbating Alzheimer-like pathology.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

The moral dilemma of ICU nurses in end-of-life care: A meta-synthesis.

Nursing ethics·2026
Same author

Case Report: Localized hyperinflammatory response in the bulla after mosquito bites in a patient with systemic lupus erythematosus.

Frontiers in immunology·2026
Same author

Multifunctional Hydrogel with Dual Functions of ROS Scavenging and Responsive Antibiotic Release for Synergistic Oral Mucositis Treatment.

ACS omega·2026

Related Experiment Video

Updated: May 27, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Pharmacogenetics in type 2 diabetes: potential implications for clinical practice.

Chunmei Huang1, Jose C Florez

  • 1Center for Human Genetic Research, Massachusetts General Hospital, Simches Research Building, Boston, MA 02114, USA. jcflorez@partners.org.

Genome Medicine
|December 1, 2011
PubMed
Summary

Pharmacogenetics explores genetic impacts on drug response, aiming for personalized medicine. While successful in rare diabetes types, its application to type 2 diabetes shows promise but faces translation barriers.

Related Experiment Videos

Last Updated: May 27, 2026

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)
09:52

Generation of High Quality Chromatin Immunoprecipitation DNA Template for High-throughput Sequencing (ChIP-seq)

Published on: April 19, 2013

Area of Science:

  • Pharmacogenomics and Genetics
  • Translational Medicine

Background:

  • Pharmacogenetics investigates genetic variations' influence on drug efficacy and toxicity.
  • Pharmacogenomics extends this to a genome-wide scale, aiding drug target discovery and personalized treatment.
  • Established success in monogenic diabetes forms contrasts with ongoing research for type 2 diabetes.

Purpose of the Study:

  • To provide a contemporary overview of pharmacogenetics in diabetes.
  • To identify obstacles in translating pharmacogenetic discoveries into clinical practice for diabetes.
  • To highlight future research directions in the field.

Main Methods:

  • Review of genetic approaches including candidate gene studies, large-scale genotyping, and genome-wide association studies (GWAS).
  • Analysis of existing pharmacogenetic findings in diabetes, particularly type 2.
  • Identification of barriers to clinical implementation.

Main Results:

  • Advances in genetic technologies are yielding suggestive results for type 2 diabetes pharmacogenetics.
  • Potential for pharmacogenetic insights to inform drug targets, pathophysiology, and disease heterogeneity.
  • Significant barriers hinder the translation of these discoveries into routine clinical management.

Conclusions:

  • Pharmacogenetics holds promise for personalized treatment in type 2 diabetes, building on successes in monogenic forms.
  • Continued research and overcoming implementation challenges are crucial for clinical application.
  • Future directions involve refining genetic approaches and addressing translational hurdles.